nodes	percent_of_prediction	percent_of_DWPC	metapath
Betamethasone—CYP3A4—bone cancer	0.363	0.505	CbGaD
Betamethasone—PTGS2—bone cancer	0.355	0.495	CbGaD
Betamethasone—PTGS2—Cisplatin—bone cancer	0.0481	0.527	CbGbCtD
Betamethasone—ABCB1—Cisplatin—bone cancer	0.0159	0.174	CbGbCtD
Betamethasone—ABCB1—Doxorubicin—bone cancer	0.0106	0.117	CbGbCtD
Betamethasone—ABCB1—Methotrexate—bone cancer	0.0103	0.113	CbGbCtD
Betamethasone—CYP3A4—Doxorubicin—bone cancer	0.00636	0.0698	CbGbCtD
Betamethasone—Fluocinonide—SMO—bone cancer	0.00261	0.427	CrCbGaD
Betamethasone—CYP19A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00171	0.0489	CbGpPWpGaD
Betamethasone—NR3C2—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00167	0.0479	CbGpPWpGaD
Betamethasone—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00167	0.0477	CbGpPWpGaD
Betamethasone—PGR—Nuclear Receptors—NR1I2—bone cancer	0.00129	0.0369	CbGpPWpGaD
Betamethasone—PGR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00102	0.0292	CbGpPWpGaD
Betamethasone—NR3C2—Generic Transcription Pathway—ZNF77—bone cancer	0.000853	0.0244	CbGpPWpGaD
Betamethasone—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000813	0.0233	CbGpPWpGaD
Betamethasone—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.000788	0.0226	CbGpPWpGaD
Betamethasone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.000776	0.0222	CbGpPWpGaD
Betamethasone—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000761	0.0218	CbGpPWpGaD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00076	0.0218	CbGpPWpGaD
Betamethasone—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.000744	0.0213	CbGpPWpGaD
Betamethasone—CYP19A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000735	0.0211	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.000711	0.0204	CbGpPWpGaD
Betamethasone—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000588	0.0169	CbGpPWpGaD
Betamethasone—PGR—Ovarian Infertility Genes—CDK4—bone cancer	0.000535	0.0153	CbGpPWpGaD
Betamethasone—PGR—Generic Transcription Pathway—ZNF77—bone cancer	0.000519	0.0149	CbGpPWpGaD
Betamethasone—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000498	0.0143	CbGpPWpGaD
Betamethasone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000469	0.0134	CbGpPWpGaD
Betamethasone—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000445	0.0127	CbGpPWpGaD
Betamethasone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000437	0.0125	CbGpPWpGaD
Betamethasone—CYP19A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000423	0.0121	CbGpPWpGaD
Betamethasone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.000415	0.0119	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—ZNF77—bone cancer	0.000411	0.0118	CbGpPWpGaD
Betamethasone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000409	0.0117	CbGpPWpGaD
Betamethasone—Dermatitis contact—Epirubicin—bone cancer	0.000375	0.00251	CcSEcCtD
Betamethasone—Ulcer—Doxorubicin—bone cancer	0.000371	0.00248	CcSEcCtD
Betamethasone—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	0.00037	0.0106	CbGpPWpGaD
Betamethasone—Ecchymosis—Methotrexate—bone cancer	0.000367	0.00245	CcSEcCtD
Betamethasone—Skin exfoliation—Epirubicin—bone cancer	0.000363	0.00242	CcSEcCtD
Betamethasone—Pulmonary oedema—Methotrexate—bone cancer	0.000361	0.00242	CcSEcCtD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000361	0.0103	CbGpPWpGaD
Betamethasone—Fluid retention—Epirubicin—bone cancer	0.000361	0.00241	CcSEcCtD
Betamethasone—Visual impairment—Cisplatin—bone cancer	0.000358	0.00239	CcSEcCtD
Betamethasone—Neuropathy—Epirubicin—bone cancer	0.000357	0.00238	CcSEcCtD
Betamethasone—Hiccups—Doxorubicin—bone cancer	0.000351	0.00235	CcSEcCtD
Betamethasone—CYP19A1—Ovarian Infertility Genes—CDK4—bone cancer	0.000351	0.0101	CbGpPWpGaD
Betamethasone—Dry eye—Epirubicin—bone cancer	0.000351	0.00235	CcSEcCtD
Betamethasone—Dermatitis contact—Doxorubicin—bone cancer	0.000347	0.00232	CcSEcCtD
Betamethasone—Eye disorder—Cisplatin—bone cancer	0.000347	0.00232	CcSEcCtD
Betamethasone—Oesophagitis—Epirubicin—bone cancer	0.000347	0.00232	CcSEcCtD
Betamethasone—Ecchymosis—Epirubicin—bone cancer	0.000343	0.0023	CcSEcCtD
Betamethasone—Budesonide—CYP3A4—bone cancer	0.000343	0.0562	CrCbGaD
Betamethasone—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000342	0.0098	CbGpPWpGaD
Betamethasone—Thrombophlebitis—Methotrexate—bone cancer	0.00034	0.00228	CcSEcCtD
Betamethasone—Diabetes mellitus—Methotrexate—bone cancer	0.000339	0.00226	CcSEcCtD
Betamethasone—Pulmonary oedema—Epirubicin—bone cancer	0.000338	0.00226	CcSEcCtD
Betamethasone—CYP19A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000338	0.00968	CbGpPWpGaD
Betamethasone—Fluticasone furoate—CYP3A4—bone cancer	0.000336	0.0551	CrCbGaD
Betamethasone—Skin exfoliation—Doxorubicin—bone cancer	0.000335	0.00224	CcSEcCtD
Betamethasone—Fluid retention—Doxorubicin—bone cancer	0.000334	0.00223	CcSEcCtD
Betamethasone—Arrhythmia—Cisplatin—bone cancer	0.000332	0.00222	CcSEcCtD
Betamethasone—Neuropathy—Doxorubicin—bone cancer	0.00033	0.00221	CcSEcCtD
Betamethasone—Alopecia—Cisplatin—bone cancer	0.000328	0.00219	CcSEcCtD
Betamethasone—Dry eye—Doxorubicin—bone cancer	0.000325	0.00217	CcSEcCtD
Betamethasone—Erythema—Cisplatin—bone cancer	0.000323	0.00216	CcSEcCtD
Betamethasone—Oesophagitis—Doxorubicin—bone cancer	0.000321	0.00215	CcSEcCtD
Betamethasone—Thrombophlebitis—Epirubicin—bone cancer	0.000318	0.00213	CcSEcCtD
Betamethasone—Ecchymosis—Doxorubicin—bone cancer	0.000318	0.00212	CcSEcCtD
Betamethasone—Diabetes mellitus—Epirubicin—bone cancer	0.000317	0.00212	CcSEcCtD
Betamethasone—Pulmonary oedema—Doxorubicin—bone cancer	0.000313	0.00209	CcSEcCtD
Betamethasone—Visual disturbance—Methotrexate—bone cancer	0.000311	0.00208	CcSEcCtD
Betamethasone—Eye pain—Epirubicin—bone cancer	0.000305	0.00204	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Methotrexate—bone cancer	0.000304	0.00204	CcSEcCtD
Betamethasone—Cardiac failure congestive—Epirubicin—bone cancer	0.000304	0.00203	CcSEcCtD
Betamethasone—Lethargy—Methotrexate—bone cancer	0.000301	0.00201	CcSEcCtD
Betamethasone—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	0.0003	0.0086	CbGpPWpGaD
Betamethasone—Ill-defined disorder—Cisplatin—bone cancer	0.0003	0.00201	CcSEcCtD
Betamethasone—NR3C1—Endoderm Differentiation—EZH2—bone cancer	0.0003	0.00859	CbGpPWpGaD
Betamethasone—Alclometasone—CYP3A4—bone cancer	0.000296	0.0485	CrCbGaD
Betamethasone—Thrombophlebitis—Doxorubicin—bone cancer	0.000295	0.00197	CcSEcCtD
Betamethasone—Osteoarthritis—Methotrexate—bone cancer	0.000295	0.00197	CcSEcCtD
Betamethasone—Increased appetite—Epirubicin—bone cancer	0.000293	0.00196	CcSEcCtD
Betamethasone—Diabetes mellitus—Doxorubicin—bone cancer	0.000293	0.00196	CcSEcCtD
Betamethasone—Malaise—Cisplatin—bone cancer	0.000292	0.00195	CcSEcCtD
Betamethasone—NR3C2—Generic Transcription Pathway—NR1I2—bone cancer	0.000289	0.00827	CbGpPWpGaD
Betamethasone—Dermatitis bullous—Epirubicin—bone cancer	0.000288	0.00193	CcSEcCtD
Betamethasone—Flunisolide—CYP3A4—bone cancer	0.000288	0.0472	CrCbGaD
Betamethasone—Anaphylactoid reaction—Epirubicin—bone cancer	0.000285	0.0019	CcSEcCtD
Betamethasone—Paramethasone—CYP3A4—bone cancer	0.000284	0.0466	CrCbGaD
Betamethasone—Eye pain—Doxorubicin—bone cancer	0.000283	0.00189	CcSEcCtD
Betamethasone—Cardiac failure—Epirubicin—bone cancer	0.000282	0.00189	CcSEcCtD
Betamethasone—Lethargy—Epirubicin—bone cancer	0.000281	0.00188	CcSEcCtD
Betamethasone—Cardiac failure congestive—Doxorubicin—bone cancer	0.000281	0.00188	CcSEcCtD
Betamethasone—Irritability—Methotrexate—bone cancer	0.000281	0.00188	CcSEcCtD
Betamethasone—Convulsion—Cisplatin—bone cancer	0.00028	0.00187	CcSEcCtD
Betamethasone—Mood swings—Methotrexate—bone cancer	0.000279	0.00187	CcSEcCtD
Betamethasone—Fluorometholone—CYP3A4—bone cancer	0.000277	0.0455	CrCbGaD
Betamethasone—CYP19A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000277	0.00795	CbGpPWpGaD
Betamethasone—Osteoarthritis—Epirubicin—bone cancer	0.000276	0.00184	CcSEcCtD
Betamethasone—Myalgia—Cisplatin—bone cancer	0.000275	0.00184	CcSEcCtD
Betamethasone—Anxiety—Cisplatin—bone cancer	0.000274	0.00183	CcSEcCtD
Betamethasone—Discomfort—Cisplatin—bone cancer	0.000272	0.00182	CcSEcCtD
Betamethasone—Increased appetite—Doxorubicin—bone cancer	0.000271	0.00182	CcSEcCtD
Betamethasone—Migraine—Epirubicin—bone cancer	0.000271	0.00181	CcSEcCtD
Betamethasone—Affect lability—Epirubicin—bone cancer	0.000271	0.00181	CcSEcCtD
Betamethasone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000269	0.00771	CbGpPWpGaD
Betamethasone—Methylprednisolone—CYP3A4—bone cancer	0.000268	0.044	CrCbGaD
Betamethasone—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000268	0.00768	CbGpPWpGaD
Betamethasone—Dermatitis bullous—Doxorubicin—bone cancer	0.000267	0.00178	CcSEcCtD
Betamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000265	0.00758	CbGpPWpGaD
Betamethasone—Anaphylactic shock—Cisplatin—bone cancer	0.000264	0.00176	CcSEcCtD
Betamethasone—Oedema—Cisplatin—bone cancer	0.000264	0.00176	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000264	0.00176	CcSEcCtD
Betamethasone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000263	0.00753	CbGpPWpGaD
Betamethasone—Cardiac arrest—Epirubicin—bone cancer	0.000262	0.00175	CcSEcCtD
Betamethasone—Infection—Cisplatin—bone cancer	0.000262	0.00175	CcSEcCtD
Betamethasone—Cardiac failure—Doxorubicin—bone cancer	0.000261	0.00175	CcSEcCtD
Betamethasone—Mood swings—Epirubicin—bone cancer	0.000261	0.00175	CcSEcCtD
Betamethasone—Lethargy—Doxorubicin—bone cancer	0.00026	0.00174	CcSEcCtD
Betamethasone—Nervous system disorder—Cisplatin—bone cancer	0.000259	0.00173	CcSEcCtD
Betamethasone—Thrombocytopenia—Cisplatin—bone cancer	0.000258	0.00173	CcSEcCtD
Betamethasone—Tachycardia—Cisplatin—bone cancer	0.000257	0.00172	CcSEcCtD
Betamethasone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000255	0.00732	CbGpPWpGaD
Betamethasone—Osteoarthritis—Doxorubicin—bone cancer	0.000255	0.00171	CcSEcCtD
Betamethasone—Hyperhidrosis—Cisplatin—bone cancer	0.000255	0.00171	CcSEcCtD
Betamethasone—Dry skin—Epirubicin—bone cancer	0.000253	0.00169	CcSEcCtD
Betamethasone—Anorexia—Cisplatin—bone cancer	0.000251	0.00168	CcSEcCtD
Betamethasone—Migraine—Doxorubicin—bone cancer	0.000251	0.00168	CcSEcCtD
Betamethasone—Affect lability—Doxorubicin—bone cancer	0.000251	0.00168	CcSEcCtD
Betamethasone—Hypokalaemia—Epirubicin—bone cancer	0.000251	0.00168	CcSEcCtD
Betamethasone—PGR—Gene Expression—ZNF77—bone cancer	0.00025	0.00716	CbGpPWpGaD
Betamethasone—Hypotension—Cisplatin—bone cancer	0.000247	0.00165	CcSEcCtD
Betamethasone—Muscular weakness—Epirubicin—bone cancer	0.000243	0.00163	CcSEcCtD
Betamethasone—Cardiac arrest—Doxorubicin—bone cancer	0.000243	0.00162	CcSEcCtD
Betamethasone—PLA2G1B—Metabolism—NDUFA12—bone cancer	0.000242	0.00693	CbGpPWpGaD
Betamethasone—Mood swings—Doxorubicin—bone cancer	0.000242	0.00162	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00024	0.00161	CcSEcCtD
Betamethasone—Paraesthesia—Cisplatin—bone cancer	0.000237	0.00158	CcSEcCtD
Betamethasone—Dry skin—Doxorubicin—bone cancer	0.000234	0.00156	CcSEcCtD
Betamethasone—Hypokalaemia—Doxorubicin—bone cancer	0.000232	0.00155	CcSEcCtD
Betamethasone—Decreased appetite—Cisplatin—bone cancer	0.000229	0.00153	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Cisplatin—bone cancer	0.000228	0.00152	CcSEcCtD
Betamethasone—Triamcinolone—CYP3A4—bone cancer	0.000226	0.0371	CrCbGaD
Betamethasone—Pain—Cisplatin—bone cancer	0.000226	0.00151	CcSEcCtD
Betamethasone—Muscular weakness—Doxorubicin—bone cancer	0.000225	0.0015	CcSEcCtD
Betamethasone—Triamcinolone—PTGS2—bone cancer	0.000221	0.0363	CrCbGaD
Betamethasone—Conjunctivitis—Methotrexate—bone cancer	0.000221	0.00148	CcSEcCtD
Betamethasone—Feeling abnormal—Cisplatin—bone cancer	0.000217	0.00145	CcSEcCtD
Betamethasone—Weight increased—Epirubicin—bone cancer	0.000217	0.00145	CcSEcCtD
Betamethasone—Weight decreased—Epirubicin—bone cancer	0.000216	0.00144	CcSEcCtD
Betamethasone—Hyperglycaemia—Epirubicin—bone cancer	0.000215	0.00144	CcSEcCtD
Betamethasone—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000215	0.00614	CbGpPWpGaD
Betamethasone—Body temperature increased—Cisplatin—bone cancer	0.000209	0.00139	CcSEcCtD
Betamethasone—Neuropathy peripheral—Epirubicin—bone cancer	0.000208	0.00139	CcSEcCtD
Betamethasone—Conjunctivitis—Epirubicin—bone cancer	0.000206	0.00138	CcSEcCtD
Betamethasone—Prednisone—CYP3A4—bone cancer	0.000205	0.0336	CrCbGaD
Betamethasone—Haemoglobin—Methotrexate—bone cancer	0.000205	0.00137	CcSEcCtD
Betamethasone—Haemorrhage—Methotrexate—bone cancer	0.000204	0.00136	CcSEcCtD
Betamethasone—Fluticasone Propionate—CYP3A4—bone cancer	0.000202	0.0331	CrCbGaD
Betamethasone—Weight increased—Doxorubicin—bone cancer	0.000201	0.00134	CcSEcCtD
Betamethasone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000201	0.00574	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—FUS—bone cancer	0.000201	0.00574	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—NT5C3A—bone cancer	0.0002	0.00574	CbGpPWpGaD
Betamethasone—Weight decreased—Doxorubicin—bone cancer	0.000199	0.00133	CcSEcCtD
Betamethasone—Hyperglycaemia—Doxorubicin—bone cancer	0.000199	0.00133	CcSEcCtD
Betamethasone—PGR—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000198	0.00567	CbGpPWpGaD
Betamethasone—Visual impairment—Methotrexate—bone cancer	0.000196	0.00131	CcSEcCtD
Betamethasone—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.000195	0.00557	CbGpPWpGaD
Betamethasone—Bradycardia—Epirubicin—bone cancer	0.000194	0.0013	CcSEcCtD
Betamethasone—Neuropathy peripheral—Doxorubicin—bone cancer	0.000193	0.00129	CcSEcCtD
Betamethasone—Haemoglobin—Epirubicin—bone cancer	0.000192	0.00128	CcSEcCtD
Betamethasone—Conjunctivitis—Doxorubicin—bone cancer	0.000191	0.00128	CcSEcCtD
Betamethasone—Haemorrhage—Epirubicin—bone cancer	0.000191	0.00128	CcSEcCtD
Betamethasone—Eye disorder—Methotrexate—bone cancer	0.00019	0.00127	CcSEcCtD
Betamethasone—Asthenia—Cisplatin—bone cancer	0.000189	0.00127	CcSEcCtD
Betamethasone—Prednisolone—CYP3A4—bone cancer	0.000189	0.031	CrCbGaD
Betamethasone—Angiopathy—Methotrexate—bone cancer	0.000185	0.00124	CcSEcCtD
Betamethasone—Visual impairment—Epirubicin—bone cancer	0.000184	0.00123	CcSEcCtD
Betamethasone—Diarrhoea—Cisplatin—bone cancer	0.000181	0.00121	CcSEcCtD
Betamethasone—Alopecia—Methotrexate—bone cancer	0.00018	0.0012	CcSEcCtD
Betamethasone—Bradycardia—Doxorubicin—bone cancer	0.00018	0.0012	CcSEcCtD
Betamethasone—Eye disorder—Epirubicin—bone cancer	0.000178	0.00119	CcSEcCtD
Betamethasone—Erythema—Methotrexate—bone cancer	0.000177	0.00119	CcSEcCtD
Betamethasone—Haemoglobin—Doxorubicin—bone cancer	0.000177	0.00119	CcSEcCtD
Betamethasone—Haemorrhage—Doxorubicin—bone cancer	0.000176	0.00118	CcSEcCtD
Betamethasone—PGR—Generic Transcription Pathway—NR1I2—bone cancer	0.000176	0.00504	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	0.000175	0.00501	CbGpPWpGaD
Betamethasone—Angiopathy—Epirubicin—bone cancer	0.000173	0.00116	CcSEcCtD
Betamethasone—Arrhythmia—Epirubicin—bone cancer	0.00017	0.00114	CcSEcCtD
Betamethasone—Visual impairment—Doxorubicin—bone cancer	0.00017	0.00114	CcSEcCtD
Betamethasone—Alopecia—Epirubicin—bone cancer	0.000169	0.00113	CcSEcCtD
Betamethasone—Vomiting—Cisplatin—bone cancer	0.000168	0.00112	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000168	0.0048	CbGpPWpGaD
Betamethasone—Rash—Cisplatin—bone cancer	0.000166	0.00111	CcSEcCtD
Betamethasone—Dermatitis—Cisplatin—bone cancer	0.000166	0.00111	CcSEcCtD
Betamethasone—Erythema—Epirubicin—bone cancer	0.000166	0.00111	CcSEcCtD
Betamethasone—Eye disorder—Doxorubicin—bone cancer	0.000165	0.0011	CcSEcCtD
Betamethasone—Ill-defined disorder—Methotrexate—bone cancer	0.000165	0.0011	CcSEcCtD
Betamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000164	0.0047	CbGpPWpGaD
Betamethasone—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000163	0.00468	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000161	0.00462	CbGpPWpGaD
Betamethasone—Angiopathy—Doxorubicin—bone cancer	0.00016	0.00107	CcSEcCtD
Betamethasone—Malaise—Methotrexate—bone cancer	0.00016	0.00107	CcSEcCtD
Betamethasone—Vertigo—Methotrexate—bone cancer	0.000159	0.00107	CcSEcCtD
Betamethasone—Arrhythmia—Doxorubicin—bone cancer	0.000158	0.00105	CcSEcCtD
Betamethasone—Nausea—Cisplatin—bone cancer	0.000157	0.00105	CcSEcCtD
Betamethasone—Alopecia—Doxorubicin—bone cancer	0.000156	0.00104	CcSEcCtD
Betamethasone—Ill-defined disorder—Epirubicin—bone cancer	0.000154	0.00103	CcSEcCtD
Betamethasone—Convulsion—Methotrexate—bone cancer	0.000154	0.00103	CcSEcCtD
Betamethasone—Erythema—Doxorubicin—bone cancer	0.000154	0.00103	CcSEcCtD
Betamethasone—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000153	0.00439	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000152	0.00437	CbGpPWpGaD
Betamethasone—Myalgia—Methotrexate—bone cancer	0.000151	0.00101	CcSEcCtD
Betamethasone—Malaise—Epirubicin—bone cancer	0.00015	0.001	CcSEcCtD
Betamethasone—Discomfort—Methotrexate—bone cancer	0.000149	0.000998	CcSEcCtD
Betamethasone—Vertigo—Epirubicin—bone cancer	0.000149	0.000998	CcSEcCtD
Betamethasone—Syncope—Epirubicin—bone cancer	0.000149	0.000996	CcSEcCtD
Betamethasone—CYP19A1—Biological oxidations—CYP3A4—bone cancer	0.000147	0.00422	CbGpPWpGaD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000147	0.00422	CbGpPWpGaD
Betamethasone—Loss of consciousness—Epirubicin—bone cancer	0.000146	0.000976	CcSEcCtD
Betamethasone—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000145	0.00416	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—KIT—bone cancer	0.000145	0.00415	CbGpPWpGaD
Betamethasone—Anaphylactic shock—Methotrexate—bone cancer	0.000145	0.000968	CcSEcCtD
Betamethasone—Hydrocortisone—CYP3A4—bone cancer	0.000145	0.0237	CrCbGaD
Betamethasone—NR3C1—Gene Expression—ZNF77—bone cancer	0.000145	0.00414	CbGpPWpGaD
Betamethasone—Convulsion—Epirubicin—bone cancer	0.000144	0.000962	CcSEcCtD
Betamethasone—Infection—Methotrexate—bone cancer	0.000144	0.000962	CcSEcCtD
Betamethasone—Hypertension—Epirubicin—bone cancer	0.000143	0.000959	CcSEcCtD
Betamethasone—Ill-defined disorder—Doxorubicin—bone cancer	0.000143	0.000953	CcSEcCtD
Betamethasone—Nervous system disorder—Methotrexate—bone cancer	0.000142	0.00095	CcSEcCtD
Betamethasone—Thrombocytopenia—Methotrexate—bone cancer	0.000142	0.000948	CcSEcCtD
Betamethasone—Myalgia—Epirubicin—bone cancer	0.000141	0.000945	CcSEcCtD
Betamethasone—Anxiety—Epirubicin—bone cancer	0.000141	0.000942	CcSEcCtD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000141	0.00403	CbGpPWpGaD
Betamethasone—Hyperhidrosis—Methotrexate—bone cancer	0.00014	0.000936	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00014	0.00401	CbGpPWpGaD
Betamethasone—Discomfort—Epirubicin—bone cancer	0.00014	0.000934	CcSEcCtD
Betamethasone—NR3C2—Gene Expression—NR1I2—bone cancer	0.000139	0.00398	CbGpPWpGaD
Betamethasone—Malaise—Doxorubicin—bone cancer	0.000139	0.000926	CcSEcCtD
Betamethasone—Vertigo—Doxorubicin—bone cancer	0.000138	0.000923	CcSEcCtD
Betamethasone—Anorexia—Methotrexate—bone cancer	0.000138	0.000923	CcSEcCtD
Betamethasone—Syncope—Doxorubicin—bone cancer	0.000138	0.000921	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000137	0.00392	CbGpPWpGaD
Betamethasone—Oedema—Epirubicin—bone cancer	0.000135	0.000906	CcSEcCtD
Betamethasone—Anaphylactic shock—Epirubicin—bone cancer	0.000135	0.000906	CcSEcCtD
Betamethasone—Hypotension—Methotrexate—bone cancer	0.000135	0.000905	CcSEcCtD
Betamethasone—Loss of consciousness—Doxorubicin—bone cancer	0.000135	0.000903	CcSEcCtD
Betamethasone—Infection—Epirubicin—bone cancer	0.000135	0.0009	CcSEcCtD
Betamethasone—Shock—Epirubicin—bone cancer	0.000133	0.000891	CcSEcCtD
Betamethasone—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	0.000133	0.00381	CbGpPWpGaD
Betamethasone—Convulsion—Doxorubicin—bone cancer	0.000133	0.00089	CcSEcCtD
Betamethasone—Nervous system disorder—Epirubicin—bone cancer	0.000133	0.000889	CcSEcCtD
Betamethasone—Thrombocytopenia—Epirubicin—bone cancer	0.000133	0.000887	CcSEcCtD
Betamethasone—Hypertension—Doxorubicin—bone cancer	0.000133	0.000887	CcSEcCtD
Betamethasone—Tachycardia—Epirubicin—bone cancer	0.000132	0.000884	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000132	0.000882	CcSEcCtD
Betamethasone—Hyperhidrosis—Epirubicin—bone cancer	0.000131	0.000876	CcSEcCtD
Betamethasone—Insomnia—Methotrexate—bone cancer	0.000131	0.000876	CcSEcCtD
Betamethasone—Myalgia—Doxorubicin—bone cancer	0.000131	0.000875	CcSEcCtD
Betamethasone—Anxiety—Doxorubicin—bone cancer	0.00013	0.000872	CcSEcCtD
Betamethasone—Paraesthesia—Methotrexate—bone cancer	0.00013	0.000869	CcSEcCtD
Betamethasone—Discomfort—Doxorubicin—bone cancer	0.000129	0.000864	CcSEcCtD
Betamethasone—Anorexia—Epirubicin—bone cancer	0.000129	0.000864	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000128	0.00368	CbGpPWpGaD
Betamethasone—Dyspepsia—Methotrexate—bone cancer	0.000127	0.000852	CcSEcCtD
Betamethasone—Hypotension—Epirubicin—bone cancer	0.000127	0.000847	CcSEcCtD
Betamethasone—CYP19A1—Biological oxidations—GSTP1—bone cancer	0.000126	0.00361	CbGpPWpGaD
Betamethasone—Decreased appetite—Methotrexate—bone cancer	0.000126	0.000842	CcSEcCtD
Betamethasone—Anaphylactic shock—Doxorubicin—bone cancer	0.000125	0.000838	CcSEcCtD
Betamethasone—Oedema—Doxorubicin—bone cancer	0.000125	0.000838	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000125	0.000836	CcSEcCtD
Betamethasone—Fatigue—Methotrexate—bone cancer	0.000125	0.000835	CcSEcCtD
Betamethasone—Infection—Doxorubicin—bone cancer	0.000125	0.000833	CcSEcCtD
Betamethasone—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	0.000124	0.00356	CbGpPWpGaD
Betamethasone—Pain—Methotrexate—bone cancer	0.000124	0.000828	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000123	0.000826	CcSEcCtD
Betamethasone—Shock—Doxorubicin—bone cancer	0.000123	0.000825	CcSEcCtD
Betamethasone—Nervous system disorder—Doxorubicin—bone cancer	0.000123	0.000822	CcSEcCtD
Betamethasone—Thrombocytopenia—Doxorubicin—bone cancer	0.000123	0.000821	CcSEcCtD
Betamethasone—Insomnia—Epirubicin—bone cancer	0.000123	0.00082	CcSEcCtD
Betamethasone—Tachycardia—Doxorubicin—bone cancer	0.000122	0.000818	CcSEcCtD
Betamethasone—PGR—Gene Expression—FUS—bone cancer	0.000122	0.0035	CbGpPWpGaD
Betamethasone—Paraesthesia—Epirubicin—bone cancer	0.000122	0.000814	CcSEcCtD
Betamethasone—Hyperhidrosis—Doxorubicin—bone cancer	0.000121	0.000811	CcSEcCtD
Betamethasone—Anorexia—Doxorubicin—bone cancer	0.000119	0.000799	CcSEcCtD
Betamethasone—Feeling abnormal—Methotrexate—bone cancer	0.000119	0.000798	CcSEcCtD
Betamethasone—Dyspepsia—Epirubicin—bone cancer	0.000119	0.000798	CcSEcCtD
Betamethasone—Gastrointestinal pain—Methotrexate—bone cancer	0.000118	0.000792	CcSEcCtD
Betamethasone—Decreased appetite—Epirubicin—bone cancer	0.000118	0.000788	CcSEcCtD
Betamethasone—Hypotension—Doxorubicin—bone cancer	0.000117	0.000783	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000117	0.000782	CcSEcCtD
Betamethasone—Fatigue—Epirubicin—bone cancer	0.000117	0.000781	CcSEcCtD
Betamethasone—Pain—Epirubicin—bone cancer	0.000116	0.000775	CcSEcCtD
Betamethasone—Urticaria—Methotrexate—bone cancer	0.000115	0.000769	CcSEcCtD
Betamethasone—Abdominal pain—Methotrexate—bone cancer	0.000114	0.000765	CcSEcCtD
Betamethasone—Body temperature increased—Methotrexate—bone cancer	0.000114	0.000765	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000114	0.000764	CcSEcCtD
Betamethasone—PGR—Signaling by ERBB4—MDM2—bone cancer	0.000114	0.00327	CbGpPWpGaD
Betamethasone—Insomnia—Doxorubicin—bone cancer	0.000113	0.000758	CcSEcCtD
Betamethasone—Paraesthesia—Doxorubicin—bone cancer	0.000113	0.000753	CcSEcCtD
Betamethasone—Feeling abnormal—Epirubicin—bone cancer	0.000112	0.000747	CcSEcCtD
Betamethasone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000111	0.00319	CbGpPWpGaD
Betamethasone—Gastrointestinal pain—Epirubicin—bone cancer	0.000111	0.000741	CcSEcCtD
Betamethasone—Dyspepsia—Doxorubicin—bone cancer	0.00011	0.000738	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000109	0.00313	CbGpPWpGaD
Betamethasone—Decreased appetite—Doxorubicin—bone cancer	0.000109	0.000729	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000108	0.000724	CcSEcCtD
Betamethasone—Fatigue—Doxorubicin—bone cancer	0.000108	0.000723	CcSEcCtD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	0.000108	0.00309	CbGpPWpGaD
Betamethasone—Dexamethasone—CYP3A4—bone cancer	0.000108	0.0177	CrCbGaD
Betamethasone—Urticaria—Epirubicin—bone cancer	0.000108	0.00072	CcSEcCtD
Betamethasone—Pain—Doxorubicin—bone cancer	0.000107	0.000717	CcSEcCtD
Betamethasone—Body temperature increased—Epirubicin—bone cancer	0.000107	0.000716	CcSEcCtD
Betamethasone—Abdominal pain—Epirubicin—bone cancer	0.000107	0.000716	CcSEcCtD
Betamethasone—NR3C1—AP-1 transcription factor network—JUN—bone cancer	0.000107	0.00305	CbGpPWpGaD
Betamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000106	0.00303	CbGpPWpGaD
Betamethasone—Dexamethasone—PTGS2—bone cancer	0.000106	0.0173	CrCbGaD
Betamethasone—Asthenia—Methotrexate—bone cancer	0.000104	0.000695	CcSEcCtD
Betamethasone—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	0.000104	0.00297	CbGpPWpGaD
Betamethasone—Feeling abnormal—Doxorubicin—bone cancer	0.000103	0.000691	CcSEcCtD
Betamethasone—NR3C2—Gene Expression—EIF2S1—bone cancer	0.000103	0.00294	CbGpPWpGaD
Betamethasone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000103	0.000686	CcSEcCtD
Betamethasone—Pruritus—Methotrexate—bone cancer	0.000102	0.000685	CcSEcCtD
Betamethasone—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.000102	0.00292	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	0.000102	0.00291	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000101	0.0029	CbGpPWpGaD
Betamethasone—Urticaria—Doxorubicin—bone cancer	9.96e-05	0.000666	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	9.95e-05	0.00285	CbGpPWpGaD
Betamethasone—Abdominal pain—Doxorubicin—bone cancer	9.91e-05	0.000663	CcSEcCtD
Betamethasone—Body temperature increased—Doxorubicin—bone cancer	9.91e-05	0.000663	CcSEcCtD
Betamethasone—Diarrhoea—Methotrexate—bone cancer	9.91e-05	0.000662	CcSEcCtD
Betamethasone—Asthenia—Epirubicin—bone cancer	9.72e-05	0.00065	CcSEcCtD
Betamethasone—Pruritus—Epirubicin—bone cancer	9.59e-05	0.000641	CcSEcCtD
Betamethasone—Dizziness—Methotrexate—bone cancer	9.57e-05	0.00064	CcSEcCtD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	9.48e-05	0.00272	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	9.39e-05	0.00269	CbGpPWpGaD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	9.28e-05	0.00266	CbGpPWpGaD
Betamethasone—Diarrhoea—Epirubicin—bone cancer	9.27e-05	0.00062	CcSEcCtD
Betamethasone—Vomiting—Methotrexate—bone cancer	9.2e-05	0.000616	CcSEcCtD
Betamethasone—Rash—Methotrexate—bone cancer	9.13e-05	0.000611	CcSEcCtD
Betamethasone—Dermatitis—Methotrexate—bone cancer	9.12e-05	0.00061	CcSEcCtD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	9.11e-05	0.00261	CbGpPWpGaD
Betamethasone—Headache—Methotrexate—bone cancer	9.07e-05	0.000607	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.06e-05	0.00259	CbGpPWpGaD
Betamethasone—Asthenia—Doxorubicin—bone cancer	8.99e-05	0.000602	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	8.97e-05	0.00257	CbGpPWpGaD
Betamethasone—Dizziness—Epirubicin—bone cancer	8.96e-05	0.000599	CcSEcCtD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	8.93e-05	0.00256	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—EZH2—bone cancer	8.92e-05	0.00255	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.89e-05	0.00254	CbGpPWpGaD
Betamethasone—Pruritus—Doxorubicin—bone cancer	8.87e-05	0.000593	CcSEcCtD
Betamethasone—CYP19A1—Metabolism—NDUFA12—bone cancer	8.84e-05	0.00253	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	8.82e-05	0.00253	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—ENO2—bone cancer	8.78e-05	0.00252	CbGpPWpGaD
Betamethasone—NR3C1—Adipogenesis—RB1—bone cancer	8.76e-05	0.00251	CbGpPWpGaD
Betamethasone—Vomiting—Epirubicin—bone cancer	8.61e-05	0.000576	CcSEcCtD
Betamethasone—Nausea—Methotrexate—bone cancer	8.6e-05	0.000575	CcSEcCtD
Betamethasone—Diarrhoea—Doxorubicin—bone cancer	8.58e-05	0.000574	CcSEcCtD
Betamethasone—Rash—Epirubicin—bone cancer	8.54e-05	0.000571	CcSEcCtD
Betamethasone—Dermatitis—Epirubicin—bone cancer	8.53e-05	0.000571	CcSEcCtD
Betamethasone—Headache—Epirubicin—bone cancer	8.49e-05	0.000568	CcSEcCtD
Betamethasone—PGR—Gene Expression—NR1I2—bone cancer	8.46e-05	0.00242	CbGpPWpGaD
Betamethasone—Dizziness—Doxorubicin—bone cancer	8.29e-05	0.000554	CcSEcCtD
Betamethasone—PTGS2—Spinal Cord Injury—CDK4—bone cancer	8.25e-05	0.00236	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—DHFR—bone cancer	8.15e-05	0.00233	CbGpPWpGaD
Betamethasone—Nausea—Epirubicin—bone cancer	8.05e-05	0.000538	CcSEcCtD
Betamethasone—Vomiting—Doxorubicin—bone cancer	7.97e-05	0.000533	CcSEcCtD
Betamethasone—Rash—Doxorubicin—bone cancer	7.9e-05	0.000529	CcSEcCtD
Betamethasone—Dermatitis—Doxorubicin—bone cancer	7.9e-05	0.000528	CcSEcCtD
Betamethasone—Headache—Doxorubicin—bone cancer	7.85e-05	0.000525	CcSEcCtD
Betamethasone—PGR—Signaling by ERBB4—EGFR—bone cancer	7.8e-05	0.00223	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	7.74e-05	0.00222	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—GNA11—bone cancer	7.61e-05	0.00218	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.57e-05	0.00217	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	7.52e-05	0.00215	CbGpPWpGaD
Betamethasone—Nausea—Doxorubicin—bone cancer	7.45e-05	0.000498	CcSEcCtD
Betamethasone—CYP19A1—Metabolism—NT5C3A—bone cancer	7.32e-05	0.0021	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—RB1—bone cancer	7.18e-05	0.00206	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—FUS—bone cancer	7.06e-05	0.00202	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.05e-05	0.00202	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—TP53—bone cancer	7.04e-05	0.00202	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—CYP3A4—bone cancer	6.9e-05	0.00198	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.87e-05	0.00197	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	6.54e-05	0.00187	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6.42e-05	0.00184	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—RGS1—bone cancer	6.35e-05	0.00182	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—GRM4—bone cancer	6.35e-05	0.00182	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	6.33e-05	0.00181	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—EIF2S1—bone cancer	6.25e-05	0.00179	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	6.2e-05	0.00178	CbGpPWpGaD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	6e-05	0.00172	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NDUFA12—bone cancer	5.9e-05	0.00169	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—GSTP1—bone cancer	5.9e-05	0.00169	CbGpPWpGaD
Betamethasone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.68e-05	0.00163	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.62e-05	0.00161	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	5.61e-05	0.00161	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—GRM1—bone cancer	5.5e-05	0.00158	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—EZH2—bone cancer	5.43e-05	0.00156	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.37e-05	0.00154	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.35e-05	0.00153	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—MMP9—bone cancer	5.17e-05	0.00148	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	5.14e-05	0.00147	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—NR1I2—bone cancer	4.89e-05	0.0014	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NT5C3A—bone cancer	4.89e-05	0.0014	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.62e-05	0.00132	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	4.31e-05	0.00124	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NDUFA12—bone cancer	4.18e-05	0.0012	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—EGFR—bone cancer	4.18e-05	0.0012	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.16e-05	0.00119	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.98e-05	0.00114	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SMO—bone cancer	3.88e-05	0.00111	CbGpPWpGaD
Betamethasone—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.68e-05	0.00105	CbGpPWpGaD
Betamethasone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.63e-05	0.00104	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.62e-05	0.00104	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—EIF2S1—bone cancer	3.61e-05	0.00103	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—GNA11—bone cancer	3.55e-05	0.00102	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—TP53—bone cancer	3.51e-05	0.00101	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NT5C3A—bone cancer	3.47e-05	0.000993	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—ATF1—bone cancer	3.3e-05	0.000944	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IL3—bone cancer	3.22e-05	0.000921	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ENO2—bone cancer	3.21e-05	0.000919	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—EZH2—bone cancer	3.14e-05	0.000899	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PTGS2—bone cancer	3.06e-05	0.000876	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—DHFR—bone cancer	2.97e-05	0.000852	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.95e-05	0.000845	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.84e-05	0.000815	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.84e-05	0.000815	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GNA11—bone cancer	2.78e-05	0.000796	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TGFBR2—bone cancer	2.75e-05	0.000788	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IGF1R—bone cancer	2.59e-05	0.000741	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NDUFA12—bone cancer	2.58e-05	0.000739	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.56e-05	0.000735	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ENO2—bone cancer	2.56e-05	0.000733	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CYP3A4—bone cancer	2.52e-05	0.000722	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.51e-05	0.000718	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.39e-05	0.000684	CbGpPWpGaD
Betamethasone—PTGS2—Disease—DHFR—bone cancer	2.37e-05	0.00068	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTP1—bone cancer	2.16e-05	0.000618	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ENO2—bone cancer	2.14e-05	0.000614	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NT5C3A—bone cancer	2.14e-05	0.000612	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.02e-05	0.000578	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—DHFR—bone cancer	1.99e-05	0.000569	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KIT—bone cancer	1.88e-05	0.000537	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GNA11—bone cancer	1.86e-05	0.000532	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—BRAF—bone cancer	1.76e-05	0.000505	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TGFBR2—bone cancer	1.72e-05	0.000493	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.69e-05	0.000485	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP3A4—bone cancer	1.68e-05	0.000482	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ENO2—bone cancer	1.52e-05	0.000435	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MDM2—bone cancer	1.48e-05	0.000423	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTP1—bone cancer	1.44e-05	0.000413	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—DHFR—bone cancer	1.41e-05	0.000404	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GNA11—bone cancer	1.32e-05	0.000377	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—JUN—bone cancer	1.28e-05	0.000368	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MMP9—bone cancer	1.25e-05	0.000358	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP3A4—bone cancer	1.19e-05	0.000342	CbGpPWpGaD
Betamethasone—PTGS2—Disease—KIT—bone cancer	1.17e-05	0.000336	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PTGS2—bone cancer	1.12e-05	0.00032	CbGpPWpGaD
Betamethasone—PTGS2—Disease—BRAF—bone cancer	1.1e-05	0.000316	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTP1—bone cancer	1.02e-05	0.000292	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—EGFR—bone cancer	1.01e-05	0.000289	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ENO2—bone cancer	9.36e-06	0.000268	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MDM2—bone cancer	9.24e-06	0.000265	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—DHFR—bone cancer	8.68e-06	0.000249	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TP53—bone cancer	8.48e-06	0.000243	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GNA11—bone cancer	8.11e-06	0.000232	CbGpPWpGaD
Betamethasone—PTGS2—Disease—EGFR—bone cancer	6.32e-06	0.000181	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTP1—bone cancer	6.29e-06	0.00018	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PTGS2—bone cancer	5.29e-06	0.000152	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PTGS2—bone cancer	3.26e-06	9.34e-05	CbGpPWpGaD
